1-(2-羟基-1-氧代丙基)哌嗪 | 100500-89-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(2-羟基-1-氧代丙基)哌嗪
• 中文别名: 哌嗪,1-(2-羟基-1-羰基丙基)-(9CI)
• 英文名称: 2-hydroxy-1-(piperazin-1-yl)propan-1-one
• 英文别名: 1-(2-hydroxypropanoyl)piperazine；2-hydroxy-1-piperazin-1-ylpropan-1-one
• CAS: 100500-89-8
• 化学式: C₇H₁₄N₂O₂
• mdl: MFCD11213712
• 分子量: 158.2
• InChiKey: JQRBBKFUEZDIRG-UHFFFAOYSA-N

物化性质

• 沸点：
  152-156 °C(Press: 0.13 Torr)
• 密度：
  1.136±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  52.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-羟基-1-氧代丙基)哌嗪 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 3.0h， 以34%的产率得到1-哌嗪-1-基丙-2-醇
  参考文献：
  名称：

  Kafka, Stanislav; Cermak, Jan; Novak, Tomas, Collection of Czechoslovak Chemical Communications, 1985, vol. 50, # 5, p. 1201 - 1211

  摘要：

  DOI：
• 作为产物：
  描述：

  哌嗪 、 乳酸乙酯 以32%的产率得到1-(2-羟基-1-氧代丙基)哌嗪
  参考文献：
  名称：

  Kafka, Stanislav; Cermak, Jan; Novak, Tomas, Collection of Czechoslovak Chemical Communications, 1985, vol. 50, # 5, p. 1201 - 1211

  摘要：

  DOI：

文献信息

• Substituted Amino-Pyrimidine Derivatives
  申请人：Endo Pharmaceuticals Inc.

  公开号：US20140038952A1

  公开（公告）日：2014-02-06

  The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新型的取代喹唑啉和吡啶并嘧啶化合物及其药用可接受的盐、前药和溶剂化合物。还提供了制备这些化合物的方法。通过向患者投予一种或多种化合物的治疗有效量，这些化合物在共同调节PI3K和/或mTOR活性方面是有用的。通过这样做，这些化合物在治疗与PI3K/AKT/mTOR途径失调相关的疾病方面是有效的。有利的是，这些化合物作为双重PI3K/mTOR抑制剂发挥作用。可以使用这些化合物治疗各种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINES COMME INHIBITEURS DE LA KINASE RET
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2017011776A1

  公开（公告）日：2017-01-19

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供了一般式I的化合物及其立体异构体和药用可接受的盐或溶剂，其中A、B、D、E、X1、X2、X3和X4的含义如规范中所述，这些化合物是RET激酶的抑制剂，可用于治疗和预防可以用RET激酶抑制剂治疗的疾病，包括由RET激酶介导的疾病或紊乱。
• PYRROLE [2, 1-F][1, 2, 4]TRIAZINE DERIVATIVE AND ANTITUMOR EFFECT THEREOF
  申请人：Pharmablock (Nanjing) R&D Co., Ltd.

  公开号：EP2857402A1

  公开（公告）日：2015-04-08

  Disclosed are a pyrrolo[2,1-f][1,2,4]triazine derivative of Formula (I) and use thereof for treating tumors. The compound has remarkable antiproliferative activity for a variety of human tumor cell lines, and is useful for treating cancers, and especially solid tumors such as gastric cancer, lung cancer, liver cancer, breast cancer, colon cancer, prostatic cancer, and oral cancer.

  公开了一种Formula (I)的吡咯并[2,1-f][1,2,4]三嗪衍生物及其用于治疗肿瘤的用途。该化合物对多种人类肿瘤细胞系具有显著的抗增殖活性，可用于治疗癌症，特别是固体肿瘤，如胃癌、肺癌、肝癌、乳腺癌、结肠癌、前列腺癌和口腔癌。
• Novel 2,5-Substituted Pyrimidines
  申请人：Grunenthal GmbH

  公开号：US20160024053A1

  公开（公告）日：2016-01-28

  The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.

  该发明涉及一种新型的取代紧缩嘧啶化合物，其一般式为(I)，其中化学基团、取代基和指数如描述中所定义，并且其用作药物，特别是用作治疗通过抑制PDE4酶可治疗的状况和疾病的药物。
• [EN] QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS<br/>[FR] DERIVES DE QUINAZOLINE UTILISES COMME AGENTS ANTI-TUMEUR
  申请人：ASTRAZENECA AB

  公开号：WO2005026152A1

  公开（公告）日：2005-03-24

  A quinazoline derivative of the formula (I): (A chemical formula should be inserted here - please see paper copy enclosed) Formula I wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.

  一种喹唑啉衍生物的化学式（I）：（请参阅附上的纸质副本以获取化学式）化学式 I，其中取代基如文本中定义的那样，用于生产抗增殖作用，该作用通过在温血动物（如人）中部分或完全抑制erbB2受体酪氨酸激酶而产生。